A Phase 1-2 Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors

Trial Profile

A Phase 1-2 Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs EFT 508 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Effector Therapeutics
  • Most Recent Events

    • 06 Jun 2017 Preliminary results (n=28) assessing the safety and tolerability of eFT508 in patients with advanced solid tumors, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 05 Jun 2017 Results published in an Effector Therapeutics media release.
    • 05 Jun 2017 According to an Effector Therapeutics media release, initial phase II efficacy data is anticipated in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top